Published in J Clin Invest on January 15, 1996
The mechanism of an immature secretion phenotype of a highly frequent naturally occurring missense mutation at codon 97 of human hepatitis B virus core antigen. J Virol (1999) 1.76
Subtype-independent immature secretion and subtype-dependent replication deficiency of a highly frequent, naturally occurring mutation of human hepatitis B virus core antigen. J Virol (1999) 1.39
Host ethnicity and virus genotype shape the hepatitis B virus-specific T-cell repertoire. J Virol (2008) 1.21
Functional characterization of naturally occurring variants of human hepatitis B virus containing the core internal deletion mutation. J Virol (1998) 1.10
A defective interference-like phenomenon of human hepatitis B virus in chronic carriers. J Virol (1998) 1.07
Preliminary results of Thymosin-a1 versus interferon-alpha-treatment in patients with HBeAg negative and serum HBV DNA positive chronic hepatitis B. World J Gastroenterol (2001) 0.99
Discovery of naturally processed and HLA-presented class I peptides from vaccinia virus infection using mass spectrometry for vaccine development. Vaccine (2009) 0.96
Vaccinia peptides eluted from HLA-DR1 isolated from virus-infected cells are recognized by CD4+ T cells from a vaccinated donor. J Proteome Res (2008) 0.92
A randomized controlled clinical trial on the treatment of Thymosin a1 versus interferon-alpha in patients with hepatitis B. World J Gastroenterol (2001) 0.90
Associations between HLA class I alleles and escape mutations in the hepatitis B virus core gene in New Zealand-resident Tongans. J Virol (2010) 0.90
Cytotoxic T lymphocyte responses and CTL epitope escape mutation in HBsAg, anti-HBe positive individuals. Gut (2000) 0.89
Efficacy of thymosin alpha-1 and interferon alpha in treatment of chronic viral hepatitis B: a randomized controlled study. World J Gastroenterol (2006) 0.88
Variability and conservation in hepatitis B virus core protein. BMC Microbiol (2005) 0.88
Molecular biology of hepatitis B virus: effect of nucleotide substitutions on the clinical features of chronic hepatitis B. Med Mol Morphol (2006) 0.87
Complete hepatitis B virus genome analysis in HBsAg positive mothers and their infants with fulminant hepatitis B. BMC Gastroenterol (2004) 0.86
Strategy for identifying dendritic cell-processed CD4+ T cell epitopes from the HIV gag p24 protein. PLoS One (2012) 0.86
Comparison of complete sequences of hepatitis B virus genotype C between inactive carriers and hepatocellular carcinoma patients before and after seroconversion. J Gastroenterol (2007) 0.82
Immunoprevalence and immunodominance of HLA-Cw*0801-restricted T cell response targeting the hepatitis B virus envelope transmembrane region. J Virol (2013) 0.81
Infectious diseases and immunity: special reference to major histocompatibility complex. Emerg Infect Dis (1997) 0.81
The two different states of hepatitis B virus DNA in asymptomatic carriers: HBe-antigen-positive versus anti-HBe-positive asymptomatic carriers. Dig Dis Sci (1998) 0.80
A biochemical and structural analysis of genetic diversity within the HLA-A*11 subtype. Immunogenetics (2005) 0.79
Immunogenicity of twenty peptides representing epitopes of the hepatitis B core and surface antigens by IFN-γ response in chronic and resolved HBV. BMC Immunol (2015) 0.76
Mutations in hepatitis B virus core regions correlate with hepatocellular injury in Chinese patients with chronic hepatitis B. World J Gastroenterol (2005) 0.75
The epitopes of influenza nucleoprotein recognized by cytotoxic T lymphocytes can be defined with short synthetic peptides. Cell (1986) 14.96
Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22 707 men in Taiwan. Lancet (1981) 13.54
Hepatitis B virus immunopathogenesis. Annu Rev Immunol (1995) 8.62
Association of class I major histocompatibility heavy and light chains induced by viral peptides. Nature (1989) 7.11
Empty MHC class I molecules come out in the cold. Nature (1990) 5.53
Hepatitis B virus gene function: the precore region targets the core antigen to cellular membranes and causes the secretion of the e antigen. Proc Natl Acad Sci U S A (1986) 4.73
Natural variants of cytotoxic epitopes are T-cell receptor antagonists for antiviral cytotoxic T cells. Nature (1994) 4.42
Cytotoxic T lymphocyte response to hepatitis C virus-derived peptides containing the HLA A2.1 binding motif. J Clin Invest (1995) 3.47
Direct binding of peptide to empty MHC class I molecules on intact cells and in vitro. Cell (1990) 3.44
HLA A2 restricted cytotoxic T lymphocyte responses to multiple hepatitis B surface antigen epitopes during hepatitis B virus infection. J Immunol (1993) 3.42
Cytotoxic T lymphocytes recognize an HLA-A2-restricted epitope within the hepatitis B virus nucleocapsid antigen. J Exp Med (1991) 2.88
HLA class I-restricted human cytotoxic T cells recognize endogenously synthesized hepatitis B virus nucleocapsid antigen. Proc Natl Acad Sci U S A (1991) 2.83
HLA-A31- and HLA-Aw68-restricted cytotoxic T cell responses to a single hepatitis B virus nucleocapsid epitope during acute viral hepatitis. J Exp Med (1993) 2.49
A naturally occurring peptide recognized by alloreactive CD8+ cytotoxic T lymphocytes in association with a class I MHC protein. Cell (1992) 2.34
Acute exacerbations of chronic type B hepatitis are accompanied by increased T cell responses to hepatitis B core and e antigens. Implications for hepatitis B e antigen seroconversion. J Clin Invest (1992) 2.20
T cell responses and virus evolution: loss of HLA A11-restricted CTL epitopes in Epstein-Barr virus isolates from highly A11-positive populations by selective mutation of anchor residues. J Exp Med (1994) 2.04
Intrahepatic distribution of hepatitis B surface and core antigens in chronic hepatitis B virus infection. Hepatocyte with cytoplasmic/membranous hepatitis B core antigen as a possible target for immune hepatocytolysis. Gastroenterology (1987) 2.02
Viral persistence. Cell (1989) 2.02
Recognition of hepatitis B virus envelope proteins by liver-infiltrating T lymphocytes in chronic HBV infection. J Immunol (1989) 2.00
Virus escape from CTL recognition. J Exp Med (1994) 1.97
Hepatitis B virus (HBV)-specific cytotoxic T-cell response in humans: production of target cells by stable expression of HBV-encoded proteins in immortalized human B-cell lines. J Virol (1992) 1.94
The role of beta 2-microglobulin in peptide binding by class I molecules. Science (1990) 1.80
Selective killing of hepatitis B envelope antigen-specific B cells by class I-restricted, exogenous antigen-specific T lymphocytes. Nature (1990) 1.74
Biologic and prognostic significance of hepatocyte hepatitis B core antigen expressions in the natural course of chronic hepatitis B virus infection. J Hepatol (1987) 1.59
Identification of peptide sequences that potentially trigger HLA-A2.1-restricted cytotoxic T lymphocytes. Eur J Immunol (1993) 1.55
Cell cycle regulation of nuclear localization of hepatitis B virus core protein. Proc Natl Acad Sci U S A (1993) 1.55
Reconstitution by MHC-restricted peptides of HLA-A2 heavy chain with beta 2-microglobulin, in vitro. Nature (1991) 1.55
Naturally-occurring peptide antigens derived from the MHC class-I-restricted processing pathway. Immunol Today (1991) 1.37
Immunology and the liver. Hepatology (1991) 1.31
Mass spectrometric identification of a naturally processed melanoma peptide recognized by CD8+ cytotoxic T lymphocytes. J Exp Med (1995) 1.24
Excess beta 2 microglobulin promoting functional peptide association with purified soluble class I MHC molecules. Nature (1991) 1.22
Precore mutations and core clustering mutations in chronic hepatitis B virus infection. Gastroenterology (1993) 1.21
Variations in codons 84-101 in the core nucleotide sequence correlate with hepatocellular injury in chronic hepatitis B virus infection. J Clin Invest (1992) 1.18
Immune response to hepatitis B virus proteins: relevance of the murine model. Semin Liver Dis (1991) 1.15
Preparation of membrane fractions. Methods Enzymol (1990) 1.04
Flow-cytometric determination of peptide-class I complex formation. Identification of p53 peptides that bind to HLA-A2. Hum Immunol (1994) 1.00
Methods to study peptides associated with MHC class I molecules. Curr Opin Immunol (1994) 0.96
Low frequency of cytotoxic liver-infiltrating T lymphocytes specific for endogenous processed surface and core proteins in chronic hepatitis B. J Infect Dis (1993) 0.86
Hepatitis B virus-specific cytotoxic T lymphocyte responses in patients with acute and chronic hepatitis B virus infection. J Hepatol (1994) 0.85
Analysis of MHC-presented peptides: applications in autoimmunity and vaccine development. Immunol Today (1994) 0.81
Characterization of T Cell Clones Specific to a Determinant of Hepatitis B Virus Core and e Antigens in Chronic Type B Hepatitis: Implication for a T Cell Mechanism of HBV Immunopathogenesis. J Biomed Sci (1994) 0.80
Hepatitis B virus-DNA transfected myeloma cell-specific cytotoxic T cells in chronic hepatitis B patients. Virology (1992) 0.78
Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study. Lancet (2003) 13.79
Antibacterial agents that inhibit lipid A biosynthesis. Science (1996) 3.38
Monte Carlo EM for missing covariates in parametric regression models. Biometrics (1999) 3.17
Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy. Hepatology (1999) 3.11
Dbp5p, a cytosolic RNA helicase, is required for poly(A)+ RNA export. EMBO J (1998) 2.90
The development of cirrhosis in patients with chronic type B hepatitis: a prospective study. Hepatology (1988) 2.75
Histone deacetylases specifically down-regulate p53-dependent gene activation. J Biol Chem (2000) 2.67
Epidemiological characteristics and risk factors of hepatocellular carcinoma. J Gastroenterol Hepatol (1997) 2.66
A prospective, randomized trial of butyl cyanoacrylate injection versus band ligation in the management of bleeding gastric varices. Hepatology (2001) 2.64
Requirement of the DEAD-Box protein ded1p for messenger RNA translation. Science (1997) 2.58
Pretreatment nomogram for prostate-specific antigen recurrence after radical prostatectomy or external-beam radiation therapy for clinically localized prostate cancer. J Clin Oncol (1999) 2.48
Transfer function analysis of the circulation: unique insights into cardiovascular regulation. Am J Physiol (1991) 2.42
Specific alterations of U1-C protein or U1 small nuclear RNA can eliminate the requirement of Prp28p, an essential DEAD box splicing factor. Mol Cell (2001) 2.29
Familial risk of hepatocellular carcinoma among chronic hepatitis B carriers and their relatives. J Natl Cancer Inst (2000) 2.23
A unique mitochondria-associated membrane fraction from rat liver has a high capacity for lipid synthesis and contains pre-Golgi secretory proteins including nascent lipoproteins. J Biol Chem (1994) 2.22
Acute exacerbations of chronic type B hepatitis are accompanied by increased T cell responses to hepatitis B core and e antigens. Implications for hepatitis B e antigen seroconversion. J Clin Invest (1992) 2.20
Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection. Hepatology (1999) 2.16
Hormonal markers and hepatitis B virus-related hepatocellular carcinoma risk: a nested case-control study among men. J Natl Cancer Inst (2001) 2.11
Detection of type 2-like T-helper cells in hepatitis C virus infection: implications for hepatitis C virus chronicity. Hepatology (1997) 2.06
Study of Dengue virus infection in SCID mice engrafted with human K562 cells. J Virol (1998) 2.03
Four yeast spliceosomal proteins (PRP5, PRP9, PRP11, and PRP21) interact to promote U2 snRNP binding to pre-mRNA. Genes Dev (1993) 2.03
Intrahepatic distribution of hepatitis B surface and core antigens in chronic hepatitis B virus infection. Hepatocyte with cytoplasmic/membranous hepatitis B core antigen as a possible target for immune hepatocytolysis. Gastroenterology (1987) 2.02
Identity of a novel swine hepatitis E virus in Taiwan forming a monophyletic group with Taiwan isolates of human hepatitis E virus. J Clin Microbiol (1999) 1.99
Activation of nuclear factor kappaB in hepatitis C virus infection: implications for pathogenesis and hepatocarcinogenesis. Hepatology (2000) 1.96
Hepatic arterial embolization in patients with unresectable hepatocellular carcinoma--a randomized controlled trial. Gastroenterology (1988) 1.91
Liver biochemical tests and dengue fever. Am J Trop Med Hyg (1992) 1.89
Clinical utility of the percentage of positive prostate biopsies in defining biochemical outcome after radical prostatectomy for patients with clinically localized prostate cancer. J Clin Oncol (2000) 1.86
Transport of hepatitis B virus precore protein into the nucleus after cleavage of its signal peptide. J Virol (1989) 1.85
Early detection of hepatocellular carcinoma in patients with chronic type B hepatitis. A prospective study. Gastroenterology (1986) 1.84
Endoscopic variceal ligation plus nadolol and sucralfate compared with ligation alone for the prevention of variceal rebleeding: a prospective, randomized trial. Hepatology (2000) 1.84
Prospective study of hepatocellular carcinoma and liver cirrhosis in asymptomatic chronic hepatitis B virus carriers. Am J Epidemiol (1997) 1.83
The arginine-rich domain of hepatitis B virus precore and core proteins contains a signal for nuclear transport. J Virol (1990) 1.79
Effects of hepatitis B virus, alcohol drinking, cigarette smoking and familial tendency on hepatocellular carcinoma. Hepatology (1991) 1.78
Generation and characterization of organ-tropism mutants of Japanese encephalitis virus in vivo and in vitro. Virology (1996) 1.76
Subcellular localization of hepatitis B core antigen in relation to hepatocyte regeneration in chronic hepatitis B. Gastroenterology (1995) 1.75
Dbp3p, a putative RNA helicase in Saccharomyces cerevisiae, is required for efficient pre-rRNA processing predominantly at site A3. Mol Cell Biol (1997) 1.74
Lack of efficacy of phenytoin in recessive dystrophic epidermolysis bullosa. Epidermolysis Bullosa Study Group. N Engl J Med (1992) 1.73
Incremental doses of dobutamine induce a biphasic response in dysfunctional left ventricular regions subtending coronary stenoses. Circulation (1995) 1.68
Non-surgical treatment of hepatocellular carcinoma. J Gastroenterol Hepatol (1997) 1.66
The pseudomonas hot-foot syndrome. N Engl J Med (2001) 1.65
Genome-wide hypomethylation in hepatocellular carcinogenesis. Cancer Res (2001) 1.64
Adherence to antiretroviral therapy among HIV-infected methadone patients: effect of ongoing illicit drug use. Am J Drug Alcohol Abuse (2000) 1.64
Characterization of nuclear targeting signal of hepatitis delta antigen: nuclear transport as a protein complex. J Virol (1992) 1.63
Clearance of the original hepatitis B virus YMDD-motif mutants with emergence of distinct lamivudine-resistant mutants during prolonged lamivudine therapy. Hepatology (2000) 1.62
Prednisolone priming enhances Th1 response and efficacy of subsequent lamivudine therapy in patients with chronic hepatitis B. Hepatology (2000) 1.62
Effects of manganese on the growth and morphology of Ureaplasma urealyticum. J Clin Microbiol (1984) 1.61
Fulminant hepatic failure in acute hepatitis C: increased risk in chronic carriers of hepatitis B virus. Gut (1999) 1.60
Cloning and expression of a novel phosphatidylethanolamine N-methyltransferase. A specific biochemical and cytological marker for a unique membrane fraction in rat liver. J Biol Chem (1993) 1.58
The human papillomavirus-16 E6 oncoprotein decreases the vigilance of mitotic checkpoints. Oncogene (1997) 1.58
Filamin A mutations cause periventricular heterotopia with Ehlers-Danlos syndrome. Neurology (2005) 1.57
Nucleic acid transport in plant-microbe interactions: the molecules that walk through the walls. Annu Rev Microbiol (2000) 1.55
Viral loads in clinical specimens and SARS manifestations. Emerg Infect Dis (2004) 1.55
Comparison of respiratory suppression methods and navigator locations for MR coronary angiography. AJR Am J Roentgenol (1997) 1.55
Antibody-directed cytotoxic agents: use of monoclonal antibody to direct the action of toxin A chains to colorectal carcinoma cells. Proc Natl Acad Sci U S A (1980) 1.54
Hepatic injury during ketoconazole therapy in patients with onychomycosis: a controlled cohort study. Hepatology (1997) 1.54
A missense mutation in type VII collagen in two affected siblings with recessive dystrophic epidermolysis bullosa. Nat Genet (1993) 1.53
A genetic defect in phosphatidylcholine biosynthesis triggers apoptosis in Chinese hamster ovary cells. J Biol Chem (1996) 1.52
Correlation of intrinsic chemoresistance of non-small-cell lung cancer cell lines with HER-2/neu gene expression but not with ras gene mutations. J Natl Cancer Inst (1993) 1.50
DNA immunization with Japanese encephalitis virus nonstructural protein NS1 elicits protective immunity in mice. J Virol (1998) 1.49
Immunogenicity and safety of an intradermal boosting strategy for vaccination against influenza in lung transplant recipients. Am J Transplant (2007) 1.47
Hepatitis C virus variants circumventing cytotoxic T lymphocyte activity as a mechanism of chronicity. Gastroenterology (1998) 1.47
Regulation of plasmodesmal transport by phosphorylation of tobacco mosaic virus cell-to-cell movement protein. EMBO J (2000) 1.45
Natural history of chronic hepatitis B virus infection in Taiwan: studies of hepatitis B virus DNA in serum. Hepatology (1985) 1.45
Role of hepatitis C and delta viruses in the termination of chronic hepatitis B surface antigen carrier state: a multivariate analysis in a longitudinal follow-up study. J Infect Dis (1994) 1.44
Clinical and histological events preceding hepatitis B e antigen seroconversion in chronic type B hepatitis. Gastroenterology (1983) 1.44
Scanning electron microscopy of normal and vasospastic monkey cerebrovascular smooth muscle cells. Neurosurgery (1991) 1.41
Inhibition of Japanese encephalitis virus infection by nitric oxide: antiviral effect of nitric oxide on RNA virus replication. J Virol (1997) 1.40
Constitutive activation of nuclear factor kappaB in hepatocellular carcinoma. Cancer (2000) 1.39
Junctional epidermolysis bullosa with pyloric stenosis presenting with electron microscopic findings suggestive of epidermolysis bullosa simplex. Pediatr Dermatol (2001) 1.39
Does a reduction in family medicine clerkship time affect educational outcomes? Fam Med (2001) 1.39
A p53 genetic polymorphism as a modulator of hepatocellular carcinoma risk in relation to chronic liver disease, familial tendency, and cigarette smoking in hepatitis B carriers. Hepatology (1999) 1.38
Transfer function analysis of autonomic regulation. II. Respiratory sinus arrhythmia. Am J Physiol (1989) 1.36
Effect of enforced expression of human bcl-2 on Japanese encephalitis virus-induced apoptosis in cultured cells. J Virol (1997) 1.35
Incidence, determinants and significance of delayed clearance of serum HBsAg in chronic hepatitis B virus infection: a prospective study. Hepatology (1991) 1.35
A case-control study of primary hepatocellular carcinoma in Taiwan. Cancer (1988) 1.35
The isolation and characterization of bilirubin diglucuronide, the major bilirubin conjugate in dog and human bile. Biochem J (1976) 1.34
Identification of a novel strain of hepatitis E virus responsible for sporadic acute hepatitis in Taiwan. J Med Virol (1998) 1.34
Improvement in diabetes control with a monitoring system based on a hand-held, touch-screen electronic diary. J Telemed Telecare (2001) 1.34
Production of monoclonal antibodies in serum free medium. J Immunol Methods (1980) 1.33
Induction of cyclin A gene expression by homocysteine in vascular smooth muscle cells. J Clin Invest (1996) 1.33
Pretherapy alanine transaminase level as a determinant for hepatitis B e antigen seroconversion during lamivudine therapy in patients with chronic hepatitis B. Asian Hepatitis Lamivudine Trial Group. Hepatology (1999) 1.32
Design and biological activities of L-163,191 (MK-0677): a potent, orally active growth hormone secretagogue. Proc Natl Acad Sci U S A (1995) 1.32
Bayesian analysis and model selection for interval-censored survival data. Biometrics (1999) 1.28